Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04437511
Recruitment Status : Recruiting
First Posted : June 18, 2020
Last Update Posted : October 18, 2021
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 14, 2023
Estimated Study Completion Date : December 19, 2023